

# Sandra Teresa G. Victorio Navarra, MD

Faculty of Medicine and Surgery  
University of Santo Tomas  
España Blvd, Sampaloc  
Manila, 1008 Metro Manila  
Philippines  
[svnavarra@ust.edu.ph](mailto:svnavarra@ust.edu.ph)

## EDUCATION

Doctor of Medicine: University of Santo Tomas Faculty of Medicine & Surgery, Manila, 1980, Cum Laude

## TEACHING EXPERIENCE

Professor, Department of Medicine, University of Santo Tomas (UST) Faculty of Medicine and Surgery, Manila (1985 to present)

- Physical Diagnosis in Medicine I (1983 – 1994). Lecturer, USTFMS Department of Physiology (1985 – 1986). Lecturer, USTFMS Department of Pharmacology (1987-1988)
- Faculty, Section of Rheumatology and Clinical Immunology, USTFMS Department of Medicine (1985 – present). Module leader of USTFMS Medicine II-Module 4 in Infectious diseases and Rheumatology (1998-2003; 2005-present). Faculty, Section of Infectious Diseases, USTFMS Department of Medicine (1984 – 2003). Lecturer, Immunology Lecture series at USTFMS (1988 – 1998)

## CLINICAL EXPERIENCE

- Internship: Santo Tomas University Hospital, Manila (1980-1981)
- Residency in Internal Medicine: Santo Tomas University Hospital, Manila (1982-1985) (Chief Resident, 1984-1985)
- Teaching Fellowship in Rheumatology and Clinical Immunology: University of Santo Tomas Faculty of Medicine & Surgery and Santo Tomas University Hospital (1985-1988)

## PROFESSIONAL MEMBERSHIP

Philippine College of Physicians – Life Member  
Philippine Rheumatology Association - Secretary (1992 – 1995), Vice-president (1996), President (1997- 1999)  
Philippine Society for Microbiology and Infectious Diseases - Member (1993 – 2001)  
Lupus Foundation of the Philippines, Inc. – Co-Founder and adviser (1994 – 2010)  
Combined Meeting 5th RAA Congress, 3rd APLAR Symposium, 5th Annual PRA as Secretary General (Jan 18-22, 1998)  
Rheumatology Association of ASEAN – Committee member (1993-1998)  
Asia-Pacific League of Associations for Rheumatology (APLAR) – Deputy Secretary-General (1996-1998), Secretary-General (1998-2000). Co-chair, Special Interest Group on SLE (2000- 2007). Chair, Education committee (2007-2010)  
Editorial Board: Santo Tomas Journal of Medicine (1985-2002), Journal of Medicine UST (2017-present); Philippines Health Guide (1995-2016); APLAR Journal of Rheumatology (1997-2004), International Journal of Rheumatic Diseases [former APLAR Journal] as senior associate editor (2005-2012); Lupus Science and Medicine (2016-present); Journal of Medicine – University of Santo Tomas (JMUST) (2017-present)  
Arthritis Care and Research Foundation of the Philippines, Inc. Co-Founder; Secretary (1999-2010); Project director, Teaching Module on Applied Rheumatology Made Simple (A.R.M.S.) (1999-present)  
Asia Pacific Arthritis & Rheumatism Council (APARC) – Council Member (1999-2002)  
Rheumatology Educational Trust Foundation, Inc. – President and CEO (2004- present) [Director of Lupus Inspired Advocacy (LUISA) and People Empowerment for Arthritis & Lupus (PEARL) projects]  
Organizing chair and course director of “Ten Topics in Rheumatology – Asia” 27-29 November 2009. UST Manila  
Course director of postgraduate course “Lupus in clinical practice” 25 Feb 2011, Diamond Hotel, Manila  
Overall chair and course director “Asian Lupus Summit” 28-30 November 2012, EDSA Shangri-la, Manila  
Course director of postgraduate course “Clinical problem-solving in Rheumatology”, 24 Nov 2013, Diamond Hotel, Manila  
Overall chair, PEARL Musicale and “The patient, the Artist” art exhibit, Oct 2014, University of Santo Tomas Hospital, Manila  
Course director- postgraduate course “Rheumatology connects”, Feb 2015, Marco Polo Hotel, Davao City  
Course director of “Lupus nephritis Forum” July 2015, St. Luke’s Medical Center, BGC, Taguig City

Overall coordinator, “Saving Mother Earth” symposium for UST medical students, trainees and staff, 23 Sept 2015  
Steering committee member and faculty of Lupus Academy (2011-present)  
Overall chair and course director: (1) Lupus Roadshow by Lupus Academy, 30 May 2016, University of Santo Tomas, Manila; (2) Lupus Roadshow by Lupus Academy, 18 Nov 2017, Iloilo City; (3) Lupus for the Internist postgraduate course, 03 May 2018, Bayleaf Intramuros, Manila; (4) Lupus Roadshow by Lupus Academy, 19 May 2018, Lorma Medical Center, La Union; (5) Musculoskeletal Imaging in Clinical Practice, 04 May 2019, Bayleaf Intramuros, Manila; (6) Lupus for the Internist, 05 May 2019, Bayleaf Intramuros, Manila; (7) Lupus Roadshow (by Lupus Academy) Webinar Series October-December 2020  
Founding member of Asia Pacific Lupus Collaboration (APLC) 2015 - present  
Founding member of Asian Lupus Nephritis Network (ALNN) 2013 – present

## **PROFESSIONAL ACTIVITIES**

- Chief, Section of Rheumatology, UST Faculty of Medicine and Surgery (until May 2020), UST Hospital (current)
- Active medical consultant, UST Hospital and St. Luke’s Medical Center (SLMC)
- President and CEO, Rheumatology Educational Trust Foundation, Inc. (RETFI)
- Secretary, USTFMS Department of Medicine, 1994 -1995
- Assistant Chairman, USTFMS Immunology Study Group, 1995 - 1999
- Chief, Section of Rheumatology, Clinical Immunology and Osteoporosis, University of Santo Tomas (UST) Faculty of Medicine and Surgery (1999- May 2020) UST Hospital (1999 – present)
- Chief, Section of Rheumatology, Allergy and Immunology, St. Luke’s Medical Center, 2000 - 2009
- Head, Joint and Bone Center, UST Hospital, 2002-2006
- Member, Committee on Residency, Internship Training, UST Hospital Department of Medicine, 1985-1994
- In-charge of curriculum integration and development, UST Department of Medicine, 1995 – 2013
- Member, Department of Medical Education, USTFMS, 1998-2002
- Assistant Medical Director for Professional Affairs, UST Hospital, 2001 - 2003
- Vice-chair for external affairs, Department of Medicine, UST Hospital, 2015-2018

## **HONORS AND DISTINCTIONS**

- Rector’s Certificate of Recognition for Research, University of Santo Tomas , Nov 21,1995.
- The National Academy of Science and Technology 1998 Outstanding Scientific Paper Award for series on Systemic Lupus Erythematosus among Filipinos, Westin, Manila, July 9, 1998.
- Teacher of the Year Award: UST Faculty of Medicine and Surgery, December 19, 1999
- Rector’s Gold Series Award for Research, University of Santo Tomas, February 28, 2001
- Distinguished Researcher Award, Philippine College of Physicians, May 14, 2002
- USTMAA Michigan Professorial Chair in Medicine for school year 2000-2001. Dissertation: “Towards a relevant and integrated medical curriculum: How far have we gone?”
- Rector’s Gold Series Award for Research, University of Santo Tomas, February 2003
- UST Gold Series Award for Research and International Publication Award, 16 March 2005
- UST Gold Series Award for Research and International Publication Award, February 2008
- UST “Dangal” Award for Outstanding Research in Health Sciences, March 2009
- “Most Inspiring Professor” by the UST Medicine Student Council, September 2009
- Exemplar in Clinical Education, Philippine College of Physicians, May 02, 2010
- UST “Dangal – Gawad Santo Domingo” Award to Lupus Inspired Advocacy (LUISA) for Outstanding Community Development, 2011
- Most Distinguished Physician, Philippine College of Physicians, May 06, 2012
- UST “Dangal – Gawad Santo Domingo” Award to People Empowerment for Arthritis and Lupus (PEARL) for “Matatanging Programang Paglilingkod sa Pamayanan”, Academic Year 2015-2016
- Rector’s Gold series award for Research and International Publication, December 2015
- Rector’s Gold series award for Research and International Publication, March 2018
- Semi-finalist, Metrobank Foundation Outstanding Teacher Award, 2019
- Doña Victoria Ty Tan (Metrobank Foundation) Professorial Chair in Medical Education, 19 December 2019
- Dr. Paulo C. Campos Award for Health Research by Philippine Association for the Advancement of Science and Technology (PhilAAST), 11 September 2020. The Asian Scientist 100 list (2021).
- APLAR Master Award (August 2021)

## PUBLICATIONS

- Victorio-Navarra STG, Dy EER, Arroyo CG, Torralba TP. Tuberculosis among Filipino patients with systemic lupus erythematosus. *Semin Arthritis Rheum* 26:628-634, Dec 1996.
- Malaviya AN, Umamaheswaran I, Victorio-Navarra STG, Perez EC, Kumar A, Sharma PN, Johny KV. Comparison of relative frequency of systemic lupus erythematosus (SLE) to rheumatoid arthritis (RA) in Kuwaitis, Indians and Filipinos: Hospital-based study. *APLAR Journal of Rheumatology* 2: 2-9, May 1998.
- Torralba TP, Li-Yu J, Navarra STV. Successful use of diltiazem in the calcinosis of a patient with connective tissue disease. *J Clin Rheumatol* 5:74-78, 1999.
- Victorio-Navarra S, Llamado LJQ, Torralba TP. Popliteal arterial hemorrhage in a chronic renal failure patient with destructive arthropathy. *J Clin Rheumatol* 5:224-227, 1999.
- Navarra STV, Saavedra SC, Cayco AV. Renal microtophi in lupus nephritis and tophaceous gout. *J Clin Rheumatol* 7:268-272, 2001.
- Navarra SV. Infectious agents in arthritis and autoimmunity. *Modern Rheumatology*. 13:97-102, 2003.
- Rubin BR, Burton R, Navarra S, Antigua J, Londono J, Pryhuber KG, Lund M, Chen E, Najarian DK, Petruschke RA, Ozturk ZE, Geba GP. Efficacy and Safety Profile of Treatment with Etoricoxib 120 mg once daily Compared with Indomethacin 50 mg Three Times Daily in Acute Gout. *Arthritis Rheum* 2004; 50: 598-606.
- Torralba TP, Ong MT, Navarra SV, et al. Normative bone mineral density values in Filipino women. *APLAR Journal of Rheumatology*. Vol 7. pp 30-37, 2004.
- Reyes CM, Navarra SV. Risk factors for stroke among Filipino patients with systemic lupus erythematosus. *APLAR Journal of Rheumatology* 8:19-22, 2005.
- Navarra SV. Immune therapy of lupus: what is on the horizon? *Nephrology Dialysis Transplantation* 2006 21(3):579-581.
- Navarra SV, Raso AA, Lichauco JJ, Tan PP. Clinical experience with infliximab among Filipino patients with rheumatic diseases. *APLAR Journal of Rheumatology* 2006;9:150-156.
- Lichauco JJ, Tankeh-Torres SA, Navarra SV, Dans LF. Philippine guidelines on the screening for tuberculosis prior to the use of biologic agents. *APLAR Journal of Rheumatology* 2006;9:184-192.3
- Navarra SV, King JO. An overview of clinical manifestations and survival of systemic lupus erythematosus patients in Asia. *APLAR Journal of Rheumatology* 2006; 9:336-341.
- Perez EC, Navarra SV. Clinical problem solving: Persistent knee arthritis and prolonged fever in a lupus patient. *APLAR Journal of Rheumatology* 2006; 9:342-346.
- Navarra SV, Villamin CAC, Baes RP, Pimenta L, Nicdao JL, Bernas GD. Increased frequency of mannose-binding lectin promoter LX haplotype among Filipinos with systemic lupus erythematosus. *Lupus* 2007; 16:147-148.
- Navarra SV. Role of infectious agents in autoimmunity. *Future Rheumatology* 2007; 2(3), 321-328
- Navarra SV, Villamin CAC, Baes RP, Pimenta L, Nicdao JL, Bernas GD. Increased frequency of mannose-binding lectin promoter LX haplotype among Filipinos with systemic lupus erythematosus. *Lupus* 2007; 16:147-148.
- Navarra SV, Rubin B, Yu Q, Smugar SS, Tershakovec AM. Association of baseline disease and patient characteristics with response to etoricoxib and indomethacin in acute gout. *Current Medical Research and Opinion* 2007; 23: 1627-1633.
- Santos-Estrella PV, Yih Chang Lin, Navarra SV. Pulmonary arterial hypertension among Filipino patients with connective tissue diseases. *Mod Rheumatol* (2007) 17: 224-227
- Li-Yu J, Navarra SV. A survey of psycho-social attributes of Filipino patients with systemic lupus erythematosus. *APLAR Journal of Rheumatology* 2007; 10:107-111
- Lanzon A, Navarra S. Causes of mortality among Filipino patients with systemic lupus erythematosus. *Phil J Internal Medicine* July/August 2008; 46:159-164.
- Villamin CAC, Navarra SV. Clinical manifestations and clinical syndromes of Filipino patients with systemic lupus erythematosus. *Mod Rheumatol* (2008); 18:161-164.
- Rhodes B, Wong A, Navarra SV, Villamin C, Vyse TJ. Genetic determinants of basal C-reactive protein expression in Filipino systemic lupus erythematosus families. *Genes and Immunity* (2008); 9:153-160.
- Hamijoyo L, Llamado LJQ, Navarra SV. Risk factors for avascular necrosis among Filipino patients with systemic lupus erythematosus. *International Journal of Rheumatic Diseases* 2008; 11:141-147.

- Tikly M, Navarra SV. Lupus in developing world – is it any different? *Best Practice & Research Clinical Rheumatol* (2008);22:643-655.
- Liang-Jing Lu, Wallace DJ, Navarra SV, Weisman MH. Lupus registries: Evolution and Challenges. *Semin Arthritis Rheum*. Nov 2008.
- Tolin MCC, Navarra SV. Severe hip and knee pain in a man with chronic tophaceous gout. *International Journal of Rheumatic Diseases* 2009; 12:57-60.
- Lanzon AE, Navarra SV. Gigantomastia in SLE successfully treated by reduction mammoplasty. *Lupus* 2009.
- Raso AP, Navarra SV, Li-Yu J, Torralba TP. Survey of vitamin D levels among post-menopausal Filipino women with osteoporosis. *International Journal of Rheumatic Diseases* 2009; 12:225-229.
- Kung AW, Rachman IA, Adam JM, Roeshadi D, Torralba TP, Navarra SV, Gamilla A and the BonAdASIA Study Group. Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women. *International Journal of Rheumatic Diseases* 2009; 12:216-224.
- Vargas PJ, King G, Navarra SV. Central nervous system infections in Filipino patients with systemic lupus erythematosus. *International Journal Rheumatic Diseases* 2009; 12:234-238.
- Gerona Jovie G., Navarra SV. Salmonella infections in patients with systemic lupus erythematosus: a case series. *International Journal Rheumatic Diseases* 2009; 12:319-323.
- Robinson D, Aguilar D, Schoenwetter M, Dubois R, Russak S, Ramsey-Goldmann R, Navarra S, Hsu B, Revicki D, Cella D, Rapaport MH, Renahan K, Ressler R, Wallace D, Weisman M. Impact of systemic lupus erythematosus on health, family and work: The patient perspective. *Arthritis Care and Research*, Vol. 62 No.2 February 2010, 266-273.
- Soldevilla H, Molina RM, Navarra SV. Breast lymphoma in Sjogren's syndrome complicated by acute monocular blindness. *International Journal Rheumatic Diseases* 2010;1;13(2):164-70.
- Navarra S, Naidas OD. Management of systemic lupus erythematosus renal disease. In *Targeted treatment of the rheumatic diseases*. Eds. MH Weisman et al. Saunders Elsevier Philadelphia 2010. ISBN 978-1-4160-9993-2, pp 108-123.
- Navarra S, Leynes MSN. Infections in systemic lupus erythematosus. *Lupus* 2010; 19:1419.
- Soldevilla HF, Briones SF, Navarra SV. Systemic lupus erythematosus following HPV: immunization or infection? *Lupus* 2012 Feb;21(2):158-61.
- Navarra SV, Ishimori MI, Uy EA, Hamijoyo L, Sama J, James JA, Holers VM, Weisman MH. Studies of Filipino patients with systemic lupus erythematosus: autoantibody profile of first-degree relatives. *Lupus*. 2011 Apr;20(5):537-43.
- Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EKM, Thomas M, Kim HY, Leon MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled phase 3 trial. *The Lancet*, EPub, 7 February 2011.
- Fernando MA, Freudenberg J, Lee A, Morris DL, Boteva L, Rhodes B, Gonzalez-Escribano, Lopez-Nevot MA, Navarra, SV, Gregersen PK, Martin J, Vyse TJ. Transancestral mapping of the MHC region in systemic lupus erythematosus identifies new independent and interacting loci at MSH5, HLA-DPB1 and HLA-G. *Ann Rheum Dis* 2012;71:777-784. doi:10.1136/annrheumdis-2011-200808.
- Jakes RW, Bae SC, Louthrenoo, Mok CC, Navarra SV, Kwon N. Systematic Review of the Epidemiology of Systemic Lupus Erythematosus in the Asia-Pacific Region: Prevalence, Incidence, Clinical Features, and Mortality. *Arthritis Care & Research* Vol. 64, No. 2, February 2012, pp 159-168 DOI 10.1002/acr.20683
- Navarra SV, Torralba TP. The musculoskeletal system and bone metabolism. In *Dubois Lupus Erythematosus and Related Syndromes*. Eds DJWallace et al. Saunders Philadelphia 2013. ISBN: 978-1-4377-1893-5, pp 333-340.
- Navarra SV, Tanangunan RM, Mikolaitis Preuss R, Kosinski M, Block JA, Jolly M. Cross-cultural validation of a disease-specific patient-reported outcome measure for lupus in Philippines. *Lupus* January 2013.
- Manzi S, Sanchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D'Cruz D, Doria A, Cooper S, Zhong J, Hough D, Freimuth W, Petri M. (2012). Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from 2 phase III trials. *Ann Rheum Dis* 2012;71:1833-384
- Petri MA, Van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth W. Baseline predictors of systemic lupus erythematosus flares. (2013). *Arthritis Rheum* Vol65 No. 8 Aug 2013 pp2143-2153.
- Wallace DJ, Navarra S, Petri MA, Gallacher A, Thomas M, Furie R, Levy RA, Van Vollenhoven RF, Cooper S, Zhong ZJ, Freimuth W, Cervera R. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. *Lupus* 2013 22:144.
- Navarra SV, Tang B, Lu L, Lin HY, Mok CC, Vatanabodee P, Suwannalai P, Hussein H, Rahman M. Risk of tuberculosis with anti-tumor necrosis factor-alpha therapy: substantially higher number of patients at risk in Asia. *International Journal of Rheumatic Dis* 2013.

- Mok CC, Yap YH, Navarra SV, Liu ZH, Zhao MH, Lu LJ, Takeuchi T, Avihingsanon Y, Yu XQ, Lapid EA, Lizardo LL, Sumethikul V, Shen N, Chen SL, Chan TM. Overview of lupus nephritis management guidelines and perspective from Asia. *Nephrology* 19 (2014) 11–20.
- Van Vollenhoven R, Mosca, Bertsias, Isenberg, Kuhn, Lerstrøm, Aringer, Bootsma, Boumpas, Bruce, Cervera, Clarke, Costedoat-Chalumeau, Czirájk, Derksen, Dörner, Gordon, Graninger, Houssiau, Inanc, Jacobsen, Jayne, Jedryka-Goral, Adrian Levitsky, Levy, Mariette, Morand, Navarra SV, Neumann, Rahman, Rovenský, Smolen, Vasconcelos, Voskuyl, Voss, Zakharova, Zoma, Schneider M. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. *van Vollenhoven RF, et al. Ann Rheum Dis* 2014;00:1–10.
- Bernal CB, Zamora LD, Navarra SV. Biologic therapies in systemic lupus erythematosus. *International Journal of Rheumatic Diseases* 2015; 18: 146–153
- Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, Wahono S, Chen SL, Jin O, Morton S, Hoi A, Huq M, Nikpour M, Morand E. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). *Ann Rheum Dis* 2015;0:1–7. doi:10.1136/annrheumdis-2015-207726.
- Mendoza E, Rillon-Tabil N, Payte JM, Navarra SV. Meta-analysis on prognostic factors of poor renal outcome in patients with lupus nephritis. *Phil J Int Med Vol* 54 No. 3 July-Sept 2016, 1-11.
- Latitude gradient influences the age of onset of rheumatoid arthritis: a worldwide survey: by GEO-RA Group. *Clin Rheumatol* November 2016. DOI 10.1007/s10067-016-3481-9
- Yoo DH, Racewicz A, Brzezicki J, Yatsyshyn R, Arteaga ET, Baranauskaite A, Abud-Mendoza C, Navarra S, Kadinov V, Sarriego IG, Hong SS, Lee SY, Park W. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. *Arthritis Res Ther.* 2016 Apr 2;18:82. doi:10.1186/s13075-016-0981-6.
- Golder V, Kandane-Rathnayake R, Hoi A, Huq M, Louthrenoo W, Yuan A, Li ZG, Shue FL, Sockalingam S, Lau CS, Lee AL, Mok MY, Lateef A, Franklyn K, Morton S, Navarra SV, Zamora LD, Wu YJ, Hamijoyo L, Chan M, O'Neill S, Goldblatt F, Morand EF, Nikpour M and for the Asia-Pacific Lupus Collaboration. Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. *Arthritis Research & Therapy* (2016) 18:260. DOI 10.1186/s13075-016-1163-2.
- Lim KK, Chan M, Navarra S, Haq SA, Lau CS. Development and implementation of Models of Care for musculoskeletal conditions in middle income and low-income Asian countries. *Best Practice & Research Clinical Rheumatology* 30 (2016) 398-419.
- Golder V, Kandane-Rathnayake R, Hoi A, Huq M, Louthrenoo W, Yuan A, Li ZG, Shue FL, Sockalingam S, Lau CS, Mok MY, Lateef A, Franklyn K, Morton S, Navarra SV, Zamora LD, Wu YJ, Hamijoyo L, Chan M, O'Neill S, Goldblatt F, Nikpour, Morand EF, for the Asia-Pacific Lupus Collaboration. Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. *Arthritis Research & Therapy* (2017) 19:62.
- van Vollenhoven R, Voskuyl A, Bertsias G, Aranow C, Aringer M, Arnaud L, Askanase A, Balázová P, Bonfa E, Bootsma H, Boumpas D, Bruce I, Cervera R, Clarke A, Coney C, Costedoat-Chalumeau N, Czirájk L, Derksen R, Doria A, Dörner T, Fischer-Betz R, Fritsch-Stork R, Gordon C, Graninger W, Györi N, Houssiau F, Isenberg D, Jacobsen S, Jayne D, Kuhn A, Le Guern V, Lerstrøm K, Levy R, MachadoRibeiro F, Mariette X, Missaykeh J, Morand E, Mosca M, Inanc M, Navarra S, Neumann I, Olesinska M, Petri M, Rahman A, Rekvig OP, Rovensky J, Shoenfeld Y, Smolen J, Tincani A, Urowitz M, van Leeuw B, Vasconcelos C, Voss A, Werth VP, Zakharova H, Zoma A, Schneider M, Ward M. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). *Ann Rheum Dis.* 2017 Mar;76(3):554-561.
- Golder V, Huq M, Franklyn K, Calderone A, Lateef A, Lau CS, Lee ALH, Navarra STV, Godfrey T, Oon S, Hoi AYB, Morand EF, Nikpour M. Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity study. *Semin Arthritis Rheum.* 2017 Jun;46(6):798-803.
- Golder V, Huq M, Franklyn K, Calderone A, Lateef A, Lau CS, Lee ALH, Navarra STV, Godfrey T, Oon S, Hoi AYB, Morand EF, Nikpour M. Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity study. *Semin Arthritis Rheum.* 2017 Jun;46(6):798-803.
- Jolly M, Toloza S, B Goker, AE Clarke, SV Navarra, D Wallace, M Weisman, CC Mok. Disease-specific quality of life in patients with

lupus nephritis. *Lupus* (2017), 1–8.

- Vista ES, Weisman MH, Ishimori M, Chen H, Bourn RL, Bruner BF, Hamijoyo L, Tanangunan R, Gal N, Robertson J, Harley J, Guthridge J, Navarra SV, James JA. Strong viral associations with SLE among Filipinos. *Lupus Science & Medicine* 2017;4.
- Costedoat-Chalumeau N, Houssiau F, Izmirly P, Le Guern V, Navarra S, Jolly M, Ruiz-Irastorza G, Baron G, Hachulla E, Agmon-Levin N, Shoenfeld Y, Dall'Era F, Buyon J, Deligny C, Cervera R, Lazaro E, Bezanahary H, Leroux G, Morel N, Viallard J-F, Pineau C, Galicier L, Van Vollenhoven R, Tincani A, Nguyen H, Gondran G, Zahr N, Pouchot J, Piette J-C, Petri M, Isenberg D. A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and by Self-Administered Questionnaires. *Clinical Pharmacology & Therapeutics* (2018).
- Kandane-Rathnayake R, Golder V, Louthrenoo W, Luo SF, Jan Wu YJ, Li Z, An Y, Lateef A, Sockalingam S, Navarra SV, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, O'Neill S, Goldblatt F, Hao Y, Zhang Z, Al-Saleh J, Khamashta M, Takeuchi T, Tanaka Y, Bae SC, Lau CS, Hoi A, Nikpour M, Morand EF. Development of Asia Pacific Lupus Collaboration cohort. *Int J Rheum Dis*. 2018 Nov 5.
- Mease P, van der Heijde D, Landewé R, Mpofo S, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Meiser K, Readie A, Pricop L, Abrams K. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. *Ann Rheum Dis*. 2018 Jun;77(6):890-897.
- Mosca M1, Costenbader KH, Johnson SR, Lorenzoni V, Sebastiani GD, Hoyer BF, Navarra S, Bonfa E, Ramsey-Goldman R, MedinaRosas J, Piga M, Tani C, Tedeschi SK, Dörner T, Aringer M, Touma Z. How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria. *Arthritis Rheumatol*. 2019 Jan;71(1):91-98. doi: 10.1002/art.40674.
- Rovin BH, Solomons N, Pendergraft WF, Dooley MA, Tumlin J, Romero-Diaz J, Lysenko L, Navarra SV, Huizinga RB; AURA-LV Study Group. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. *Kidney Int*. 2019 Jan;95(1):219-231.
- Navarra SV, Torralba TP. The musculoskeletal system and bone metabolism. In *Dubois Lupus Erythematosus and Related Syndromes*. Eds DJWallace et al. Saunders Philadelphia 2019. ISBN: 978-0-323-47927-1, pp 407-417.
- Veñegas E, Geslani K, Navarra S. Hospitalizations, Renal Activity and Damage Incur the Highest Medical Costs Among Filipino Patients with Systemic Lupus Erythematosus. *Philippine Journal of Internal Medicine*. Vol 56 No 2. April - June, 2018, pp 77-81.
- Navarra SV, Tanangunan RMD, Esquibel ILC. Lupus among Filipinos: Unmet needs. *Philippine Journal of Internal Medicine*. Volume 57 Number 1 January to March, 2019, pp 1-5.
- Veñegas E, Ngo JD, Navarra SV. Gastrointestinal Vasculitis in Systemic Lupus Erythematosus: Successful Treatment with Belimumab. *Philippine Journal of Internal Medicine*. Volume 57 Number 1 January to March, 2019, pp 51-54.
- Frio MS, Navarra SV. Interstitial lung disease and pulmonary arterial hypertension in Overlap syndrome: A case report. *Journal of Medicine UST* Vol 3 Issue 1, April 2019, 309-312.
- Bayson RJD, Navarra SV. Severe Keratoderma Blenorrhagicum Simulating Psoriasis in Reactive Arthritis: A Case Report. *Philippine Journal of Internal Medicine* Volume 57 Number 4 Oct. - Dec., 2019, 235-238.
- Navarroza R, Zamora LD, Navarra SV. Serotonin syndrome masquerading as disease flare in lupus nephritis with end-stage renal disease. *Int J Rheum Dis*. 2019;00:1–4.
- Zamora L, Collante MT, Navarra SV. Risk factors for herpes zoster infection among Filipinos with systemic lupus erythematosus. *Int J Rheum Dis*. 2019;00:1–6.
- Van Vollenhoven R, Navarra SV, Levy RA, Thomas M, Heath A, Lustine T, Adamkovic A, Fettiplace J, Wang ML, Ji B, Roth D. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension. *Rheumatology* (2019) doi:10.1093/rheumatology/kez279, *Rheumatology* 2020;59:281-291.
- Mease P, van der Heijde D, Landewé R, Mpofo S, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Meiser K, Readie A, Pricop L, Abrams K. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. *Ann Rheum Dis* 2018;77:890–897. doi:10.1136/annrheumdis-2017-212687.
- Kandane-Rathnayake R, Kent JR, Louthrenoo W, Luo SF, Wu YJ, Lateef A, Golder V, Sockalingam S, Navarra S, Zamora L, Hamijoyo L,

Katsumata Y, Harigai M, Chan M, O'Neill S, Goldblatt F, Lau CS, Hoi A, Nikpour M, Morand E. Longitudinal associations of active renal disease with irreversible organ damage accrual in systemic lupus erythematosus. *Lupus* (Oct 2019) 0, 1–9.

- Golder V, Kandane-Rathnayake R, Huq M, Nim HT, Louthrenoo W, Luo SF, Wu YJ, Lateef A, Sockalingam S, Navarra SV, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, O'Neill S, Goldblatt F, Lau CS, Li ZG, Hoi A, Nikpour M, Morand E, for the Asia-Pacific Lupus Collaboration. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. *Lancet Rheumatol* 2019; 1: e95–102.
- Jolly M, Sethi B, O'Brien C, Sequeira W, Block JA, Toloza S, Bertoli A, Blazevic I, Vilá LM, Moldovan I, Torralba KD, Cicognani E, Mazzoni D, Hasni S, Goker B, Haznedaroglu S, Bourre-Tessier J, Navarra SV, Mok CC, Clarke A, Weisman M, Wallace D. Drivers of Satisfaction With Care for Patients With Lupus. *ACR Open Rheumatol*. 2019 Nov 6;1(10):649-656. doi: 10.1002/acr2.11085. eCollection 2019 Dec.
- Jolly M, Sequeira W, Block JA, Toloza S, Bertoli A, Blazevic I, Vila LM, Moldovan I, Torralba KD, Mazzoni D, Cicognani E, Hasni S, Goker B, Haznedaroglu S, Bourre-Tessier J, Navarra SV, Mok CC, Weisman M, Clarke AE, Wallace D, Alarcón G. Sex Differences in Quality of Life in Patients With Systemic Lupus Erythematosus. *Arthritis Care Res (Hoboken)*. 2019;71(12):1647-1652. doi:10.1002/acr.23588
- Navarra SV, Zamora LD, Collante MT. Lupus education for physicians and patients in a resource-limited setting. *Clin Rheumatol* 39, 697–702 (2020). <https://doi.org/10.1007/s10067-019-04795-9>.
- Ho KY, Cardosa MS, Chaiamnuay S, Hidayat R, Ho HQT, Kamil O, Mokhtar SA, Nakata K, Navarra SV, Nguyen VH, Pinzon R, Tsuruoka S, Yim HB, Choy E. Practice Advisory on the Appropriate Use of NSAIDs in Primary Care. *J Pain Res*. 2020;13:1925-1939 <https://doi.org/10.2147/JPR.S247781>
- van der Heijde D, Mease PJ, Landewé RBM, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Zhu X, Ligozio G, Readie A, Mpofo S, Pricop L. Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. *Rheumatology (Oxford)*. 2020;59(6):1325-1334. doi: 10.1093/rheumatology/kez420. PMID: 31586420; PMCID: PMC7244782.
- Cho, J., Kandane-Rathnayake, R., Louthrenoo, W., Hoi, A., Golder, V., Chen, Y.-H., Luo, S.F., Wu, Y.-J.J., Hamijoyo, L., Lau, C.S., Navarra, S., Zamora, L., Tee, M., Flora, A., Jr, Li, Z.-G., An, Y., Sockalingam, S., Katsumata, Y., Harigai, M., Hao, Y., Zhang, Z., Kikuchi, J., Takeuchi, T., Basnayake, D., Goldblatt, F., Chan, M., Ng, K.P.L., Bae, S.-C., Oon, S., O'Neill, S., Gibson, K., Kumar, S., Law, A.H.N., Tugnet, N., Tanaka, Y., Nikpour, M., Morand, E. and Lateef, A. (2020), COVID-19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration. *Int. J. Rheum. Dis.*, 23: 1255-1257. <https://doi.org/10.1111/1756-185X.13937>.
- Touma Z, Cervera R, Brinks R, Lorenzoni V, Tani C, Hoyer BF, Costenbader KH, Sebastiani GD, Navarra SV, Bonfa E, Ramsey-Goldman R, Tedeschi SK, Dörner T, Johnson SR, Aringer M, Mosca M; American College of Rheumatology/European League Against Rheumatism Group. Associations Between Classification Criteria Items in Systemic Lupus Erythematosus. *Arthritis Care Res (Hoboken)*. 2020 Dec;72(12):1820-1826. doi: 10.1002/acr.24078. Epub 2020 Nov 7. PMID: 31560454.
- Cuenco FM, Navarra SV. Association of Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) to Disease Activity in Filipino Lupus Patients. *Journal of Medicine UST* 2020, 4, 1. doi: 10.35460/2546-1621.2019-0043
- Cuenco FM, Navarra SV. Tocilizumab for refractory Adult-Onset Still's Disease: Report of three cases. *Phil J Int Med Vol* 58 No.4 OctDec 2020, 158-160.
- Sheikh SZ, Scheinberg MA, Wei JCC, Tegzova D, Stohl W, de Toledo RA, Mucenic T, Banfi MRA, Maksimowicz-McKinnon K, AbudMendoza C, Navarra S, Garcia M, Garcia-De La Torre I, Ros JO, Levy RA, Bass DL, Terrés JR, Punwaney R, Harris J, Nami A, Pierce A, Thorneloe KS, Ji B, and Roth DA. Mortality and adverse events of special interest with intravenous belimumab for adults with active,6 autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial. *Lancet Rheumatol* 2021; 3: e122–e130. [https://doi.org/10.1016/S2665-9913\(20\)30355-6](https://doi.org/10.1016/S2665-9913(20)30355-6).
- Bergantin MRG, Navarra SV. Infection in Pregnancy (Section four), in *Practical management of the pregnant patient with rheumatic disease*. Eds Schreiber K, Chakravarty E, Ostensen M. Oxford University Press January 2021. ISBN: 9780198845096.
- Kandane-Rathnayake R, Louthrenoo W, Golder V, Luo SF, Wu YJ, Lateef A, Cho J, Li Z, An Y, Hamijoyo L, Navarra S, Zamora L,

Katsumata Y, Harigai M, Sockalingam S, Chan M, Chen YH, O'Neill S, Goldblatt F, Hao Y, Zhang Z, Kikuchi J, Takeuchi T, Lau CS, Nikpour M, Morand E, Hoi A; Asia Pacific Lupus Collaboration. Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study. *Rheumatology (Oxford)*. 2021 Mar 10:keab217. doi: 10.1093/rheumatology/keab217. Epub ahead of print. PMID: 33693676.

- Mok CC, Hamijoyo L, Kasitanon N, Chen DY, Chen S, Yamaoka K, Oku K, Li MT, Zamora L, Bae SC, Navarra SV, Morand EF, Tanaka Y.

The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. *The Lancet Rheumatology* 2021, ISSN 2665-9913, [https://doi.org/10.1016/S2665-9913\(21\)00009-6](https://doi.org/10.1016/S2665-9913(21)00009-6)

- Oku K, Hamijoyo L, Kasitanon N, Li MT, Navarra S, Morand E, Tanaka Y, Mok CC. Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements. *Int J Rheum Dis*. 2021 May 17. doi: 10.1111/1756-185X.14125. Epub ahead of print. PMID: 33999518.
- Rovin BR, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, Gibson K, Kaplan J, Lisk L, Navarra S, Parikh SV, Randhawa S, Solomons N, Huizinga RB. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. *The Lancet* 2021, ISSN 0140-6736, [https://doi.org/10.1016/S0140-6736\(21\)00578-X](https://doi.org/10.1016/S0140-6736(21)00578-X).
- Kandane-Rathnayake, Rangi; Louthrenoo, Worawit; Luo, Shue-Fen; Wu, Yeong-Jian; Chen, Yi-Hsing; Golder, Vera; Lateef, Aisha; Cho, Jiacai; Navarra, Sandra; Zamora, Leonid; Hamijoyo, Laniyati; Sockalingam, Sargunan; An, Yuan; Li, ZhanGuo; Montes, Ricardo; Oon, Shereen; Katsumata, Yasuhiro; Harigai, Masayoshi; Hao, Yanjie; Zhang, Zhuoli; Chan, Madelynn; Kikuchi, Jun; Takeuchi, Tsutomu; Goldblatt, Fiona; O'Neill, Sean; Bae, Sang-Cheol; Lau, Chak-Sing; Hoi, Alberta; Karyekar, Chetan; Nikpour, Mandana; Morand, Eric. Patterns of medication use in systemic lupus erythematosus – a multicentre cohort study. *ePub ahead of print. Arthritis Care and Research* July 2021.
- Philip J Mease, Robert Landewé, Proton Rahman, Hasan Tahir, Atul Singhal, Elke Boettcher, Sandra Navarra, Aimee Readie, Shephard Mpfu, Eumorphia Maria Delicha, Luminita Pricop and Desirée van der Heijde. Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. *RMD Open* 2021;7:e001600. doi: 10.1136/rmdopen-2021-001600
- Jolly M, Sehgal V, Arora S, Azizoddin D, Pinto B, Sharma A, Devilliers H, Inoue M, Toloza S, Bertoli A, Blazevic I, Vilá L, Moldovan I, Torralba KD, Mazzoni D, Cicognani E, Hasni S, Goker B, Haznedaroglu S, Bourre-Tessier J, Navarra SV, Clarke A, Weisman M, Wallace D, Mok CC. Does hydroxychloroquine improve patient reported outcomes in patients with lupus? *Lupus*. 2021;30(11):1790-1798. doi:10.1177/09612033211033983
- Chopra A, Lin HY, Navarra SV, Saeed MA, Sockalingam S, Thongpooswan S, Jois R, Salim B, Gavin Lee KW, Lau TC, Wee J. Rheumatoid arthritis management in the APLAR region: Perspectives from an expert panel of rheumatologists, patients and community oriented program for control of rheumatic diseases. *Int J Rheum Dis*. 2021 Sep;24(9):1106-1111. doi: 10.1111/1756-185X.14185. Epub 2021 Aug 10. PMID: 34375036.
- Brunner HI, Abud-Mendoza C, Mori M, Pilkington C, Syed R, Takei S, Viola D, Furie R, Navarra S, Zhang F, Bass DL, Eriksson G, Hammer A, Ji B, Okily M, Roth D, Quasny H, Ruperto N. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. *RMD Open* 2021;7:e001747. doi: 10.1136/rmdopen-2021-001747.
- Kasitanon N, Hamijoyo L, Li MT, Oku K, Navarra S, Tanaka Y, Mok CC. Management of non-renal manifestations of systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements. *Int J Rheum Dis*. 2022 Aug 2. doi: 10.1111/1756-185X.14413. Epub ahead of print. PMID: 35916201.
- Victoria P. Werth, M.D., Richard A. Furie, M.D., Juanita Romero-Diaz, M.D., Sandra Navarra, M.D., Kenneth Kalunian, M.D., Ronald F. van Vollenhoven, M.D., Filippa Nyberg, M.D., Benjamin H. Kaffenberger, M.D., Saira Z. Sheikh, M.D., Goran Radunovic, Ph.D., Xiaobi Huang, Ph.D., George Clark, B.S., et al., for the LILAC Trial Investigators\*. Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus. *N Engl J Med* 2022; 387:321-331. DOI: 10.1056/NEJMoa2118024